New research shows that the PI3K-Akt signaling pathway plays an important role in the tumor immune microenvironment, affecting the efficacy of the immune checkpoint inhibitors (Li et al., 2018; Cristofoletti et al., 2019). The gene discussed is AKT1; the disease is neoplasm.